Investigational Drug Information for Tirabrutinib
✉ Email this page to a colleague
What is the drug development status for Tirabrutinib?
Tirabrutinib is an investigational drug.
There have been 9 clinical trials for Tirabrutinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2017.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Lymphoid, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Gilead Sciences, Ono Pharmaceutical Co. Ltd, and German CLL Study Group.
There are forty-one US patents protecting this investigational drug and four hundred and seventy-one international patents.
Summary for Tirabrutinib
| US Patents | 41 |
| International Patents | 471 |
| US Patent Applications | 236 |
| WIPO Patent Applications | 134 |
| Japanese Patent Applications | 13 |
| Clinical Trial Progress | Phase 2 (2017-05-01) |
| Vendors | 40 |
Recent Clinical Trials for Tirabrutinib
| Title | Sponsor | Phase |
|---|---|---|
| Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) | Ono Pharmaceutical Co. Ltd | Phase 2 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria | Gilead Sciences | Phase 2 |
| Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome | Galapagos NV | Phase 2 |
Clinical Trial Summary for Tirabrutinib
Top disease conditions for Tirabrutinib
Top clinical trial sponsors for Tirabrutinib
US Patents for Tirabrutinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tirabrutinib | ⤷ Sign Up | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Tirabrutinib | ⤷ Sign Up | Prophylactic agent and/or therapeutic agent for diffuse large B-cell lymphoma | ONO PHARMACEUTICAL CO., LTD. (Osaka, JP) | ⤷ Sign Up |
| Tirabrutinib | ⤷ Sign Up | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Tirabrutinib | ⤷ Sign Up | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Tirabrutinib | ⤷ Sign Up | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Tirabrutinib | ⤷ Sign Up | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (Osaka, JP) | ⤷ Sign Up |
| Tirabrutinib | ⤷ Sign Up | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tirabrutinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tirabrutinib | Argentina | AR100809 | 2034-06-13 | ⤷ Sign Up |
| Tirabrutinib | Australia | AU2015274635 | 2034-06-13 | ⤷ Sign Up |
| Tirabrutinib | Brazil | BR112016028818 | 2034-06-13 | ⤷ Sign Up |
| Tirabrutinib | Canada | CA2952037 | 2034-06-13 | ⤷ Sign Up |
| Tirabrutinib | China | CN106458932 | 2034-06-13 | ⤷ Sign Up |
| Tirabrutinib | Eurasian Patent Organization | EA201692249 | 2034-06-13 | ⤷ Sign Up |
| Tirabrutinib | European Patent Office | EP3154958 | 2034-06-13 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
